Sophia Genetics SA
SOPH4.800USD
+0.200+4.35%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
325.67MMarket Cap
LossP/E TTM
More Details of Sophia Genetics SA Company
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sophia Genetics SA Info
Ticker SymbolSOPH
Company nameSOPHiA GENETICS SA
IPO dateJul 23, 2021
CEOCamblong (Jurgi)
Number of employees423
Security typeOrdinary Share
Fiscal year-endJul 23
AddressLa Piece 12
CityROLLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal codeCH-1180
Phone41216941060
Websitehttps://www.sophiagenetics.com/
Ticker SymbolSOPH
IPO dateJul 23, 2021
CEOCamblong (Jurgi)
Company Executives of Sophia Genetics SA
Name
Name/Position
Position
Shareholding
Change
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+194164.00%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+48309.00%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-17644.00%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+48309.00%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+59409.00%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+66596.00%
Dr. Philippe Menu, M.D., Ph.D.
Dr. Philippe Menu, M.D., Ph.D.
Chief Medical Officer and Chief Product Officer
Chief Medical Officer and Chief Product Officer
39.60K
-2144.00%
Mr. Daan Van Well
Mr. Daan Van Well
Chief Legal and Compliance Officer
Chief Legal and Compliance Officer
--
--
Ms. Manuela Da Silva Valente
Ms. Manuela Da Silva Valente
Chief People Officer
Chief People Officer
--
--
Dr. Tomer Berkovitz, Ph.D.
Dr. Tomer Berkovitz, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jurgi Camblong, Ph.D.
Dr. Jurgi Camblong, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
2.65M
+194164.00%
Dr. Vincent Ossipow, Ph.D.
Dr. Vincent Ossipow, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
443.81K
+48309.00%
Dr. Zhenyu Xu, Ph.D.
Dr. Zhenyu Xu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
396.61K
-17644.00%
Mr. Troy M. Cox
Mr. Troy M. Cox
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
234.25K
+48309.00%
Mr. Didier Hirsch
Mr. Didier Hirsch
Non-Executive Independent Director
Non-Executive Independent Director
133.93K
+59409.00%
Mr. Ross J Muken
Mr. Ross J Muken
President
President
128.13K
+66596.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Rest of EMEA
6.63M
34.09%
France
3.12M
16.01%
United States
2.62M
13.45%
Italy
2.51M
12.89%
Spain
1.46M
7.48%
Other
3.13M
16.08%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Feb 1
Updated: Sun, Feb 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
Other
61.13%
Shareholders
Shareholders
Proportion
Alychlo NV
10.31%
Generation Investment Management LLP
10.01%
aMoon Fund
8.12%
Akre Capital Management, LLC
5.48%
Balderton Capital (UK) LLP
4.96%
Other
61.13%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
16.43%
Venture Capital
13.08%
Family Office
10.36%
Investment Advisor
8.51%
Individual Investor
6.43%
Hedge Fund
1.06%
Bank and Trust
0.46%
Research Firm
0.06%
Pension Fund
0.03%
Other
43.58%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
81
26.90M
39.65%
-12.60M
2025Q3
76
26.89M
39.64%
-8.96M
2025Q2
89
36.69M
54.29%
-200.15K
2025Q1
93
36.63M
54.82%
-389.48K
2024Q4
93
32.50M
49.36%
-965.83K
2024Q3
91
34.60M
52.08%
+657.87K
2024Q2
92
32.44M
48.93%
+1.33M
2024Q1
93
31.91M
48.51%
+375.11K
2023Q4
91
30.61M
46.76%
-676.23K
2023Q3
91
30.34M
46.61%
-4.34M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alychlo NV
6.99M
10.31%
--
--
Feb 15, 2025
Generation Investment Management LLP
6.79M
10.01%
--
--
Sep 30, 2025
aMoon Fund
5.51M
8.12%
+577.36K
+11.70%
Feb 15, 2025
Akre Capital Management, LLC
3.72M
5.48%
--
--
Sep 30, 2025
Balderton Capital (UK) LLP
3.36M
4.96%
--
--
Feb 15, 2025
Camblong (Jurgi)
2.65M
3.91%
+194.16K
+7.89%
Feb 15, 2025
Banque Pictet & Cie S.A.
2.21M
3.25%
--
--
Sep 30, 2025
Alta Wealth Advisors LLC
1.41M
2.08%
+1.41M
--
Sep 30, 2025
Principal Global Investors (Equity)
1.39M
2.05%
-8.95K
-0.64%
Sep 30, 2025
Ossipow (Vincent)
443.81K
0.65%
+48.31K
+12.21%
Feb 15, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Health Innovation Active ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
iShares Health Innovation Active ETF
Proportion0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
